Veeva SystemsVEEV

Veeva introduced the Study Builder Agent, an AI tool that automatically configures its clinical trial software using the instructions in a study protocol. This process, which usually takes weeks of manual setup, can now be finished in as little as one day.

This is a practical example of Veeva's strategy to use AI to automate high-value tasks for drug companies. By making it faster and more consistent to start a trial, Veeva makes its R&D software more difficult for biotech firms to replace with rival tools.

Source: PRNewsWire

An unnamed top 20 biopharma company has committed to moving its sales teams onto Vault CRM. This brings the total to 14 of the 20 largest industry players that have agreed to switch to Veeva's new proprietary platform.

This migration is the most important project for Veeva right now. Moving customers from Salesforce-based technology to its own platform allows Veeva to stop paying licensing fees to Salesforce, which should lead to higher profit margins over time. Securing the world's largest drugmakers shows that the industry's biggest spenders are comfortable with the technical shift.

Source: PRNewsWire

Veeva released a new AI tool called Falcon Router that automatically identifies and routes safety reports, product complaints, and medical questions to the right teams. In the highly regulated world of drug making, companies are required to track and report every potential side effect or quality issue, a process that is usually slow and manual.

This launch is part of a broader plan to move customers toward more automated, AI-driven workflows. By making these complex regulatory tasks faster and more consistent, Veeva makes its software even harder for pharmaceutical companies to live without. If this automation proves successful, it gives customers a clear reason to pay for premium upgrades as they move onto Veeva's own platform.

Source: PRNewsWire

Amgen, a major biotech company, has committed to using Veeva Vault CRM for its global operations. This builds on a relationship that has lasted over ten years and marks a win for Veeva as it works to move its customers onto its own technology.

This move is a key step in Veeva's plan to shift customers away from software built on Salesforce and onto its own platform. By owning the technology itself, Veeva can stop paying licensing fees to Salesforce, which should leave the company with more profit from every dollar it earns. Seeing a massive player like Amgen make the switch suggests that Veeva's largest customers are comfortable with the transition.

Source: PRNewsWire

Wells Fargo set its price target for the software maker at $330. This is higher than the average analyst target of $291 and suggests the firm sees significant room for the stock to rise from its current level of about $263. While BMO Capital also nudged its target up to $270 this week, Wells Fargo's outlook is notably more optimistic. It signals confidence in the company's plan to move customers onto its own technology platform, which should eventually lower costs and help profits grow.

Source: Wells Fargo

Metrics we are tracking